Supernus Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Supernus Pharmaceuticals

08/08/2023 23:33

* Supernus Pharmaceuticals Inc  SUPN.OQ  reported a
quarterly
adjusted loss of 2 cents​​ per share for the quarter ended in
June. The mean expectation of four analysts for the quarter was
for a loss of 23 cents per share.
    * Revenue fell 20.3% to $135.56 million from a year ago;
analysts
expected $143.66 million. 
    * Supernus Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 2 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Supernus Pharmaceuticals Inc shares had risen by 7.3% this
quarter and lost 9.6% so far this year.
    * The company reported a quarterly loss of $831 thousand.
    * Wall Street's median 12-month price target for Supernus
Pharmaceuticals Inc is $43.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 8 at 10:33 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.23          -0.02          Beat
 Mar. 31 2023      0.17           0.29           Beat
 Dec. 31 2022      0.68           0.43           Missed
 Sep. 30 2022      0.36           0.03           Missed